ArticleEvidence-based complementary and alternative medicine : eCAM2022
Acetyl-11-Keto-
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Gymnemagenin-3-O-glucuronide mitigates lipopolysaccharide-induced acute lung inflammation/injury by regulating the NF-κB/MAPK signalling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications.International journal of pharmaceutics: X · 2025Review
- Targeting inflammatory dysregulation in metabolic dysfunction-associated steatotic liver disease rat model: the preventive and therapeutic effects of acetyl-11-keto-beta-boswellic acid.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- 3-Acetyl-11-Keto-β-Boswellic acid (AKBA) Attenuated 6-Hydroxydopamine (6-OHDA)-Induced Toxicity in SH-SY5Y Cells via Modulation of Akt/mTOR Pathway.Molecular neurobiology · 2025Article
- Acetyl 11-Keto Beta-Boswellic Acid Improves Neurological Functions in a Mouse Model of Multiple Sclerosis.Inflammation · 2025Article
- Assessing the efficacy of frankincense extract as a root canal irrigant against Enterococcus faecalis.PloS one · 2025Article
- From bench to bedside, boswellic acids in anti-inflammatory therapy - mechanistic insights, bioavailability challenges, and optimization approaches.Frontiers in pharmacology · 2025Review
- Acetyl-11-keto-beta-boswellic acid ameliorates monosodium iodoacetate-induced osteoarthritis in rats: implications of HMGB1/TLR4/NF-κB and Nrf2/HO-1.Frontiers in pharmacology · 2025Article
- Exploring the anti-inflammatory ingredients and potential of golden buckwheat (Food science & nutrition · 2024Article
- The Protective Effect of 11-Keto-β-Boswellic Acid against Diabetic Cardiomyopathy in Rats Entails Activation of AMPK.Nutrients · 2023Article
- Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment.Inflammopharmacology · 2022Review
- Carnosol Attenuates LPS-Induced Inflammation of Cardiomyoblasts by Inhibiting NF-Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetyl-11-keto-beta-boswellic acid (AKBA), the major component of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.